Cue Biopharma (CUE) Cash & Equivalents (2017 - 2025)

Cue Biopharma has reported Cash & Equivalents for 9 years, with the latest figure at $26.6 million in Q4 2025.

• Quarterly Cash & Equivalents rose 22.02% year-over-year to $26.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.6 million (up 22.02% YoY) and the FY2025 annual result came in at $26.6 million, up 22.02% from the prior year.
• Cash & Equivalents rose to $26.6 million in Q4 2025 per CUE's latest filing, from $11.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $73.9 million in Q2 2021 and troughed at $11.2 million in Q3 2025.
• A 5-year average of $44.5 million and a median of $46.3 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2025: Cash & Equivalents soared 212.64% in 2021, then sank 67.98% in 2025.
• Over 5 years, Cash & Equivalents stood at $52.2 million in 2021, then decreased by 1.14% to $51.6 million in 2022, then decreased by 24.25% to $39.1 million in 2023, then tumbled by 44.25% to $21.8 million in 2024, then increased by 22.02% to $26.6 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $26.6 million, $11.2 million, and $27.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.